Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0558 | 1 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 1 | 0.5 |
Echinococcus granulosus | voltage gated potassium channel | 0.0023 | 0.0135 | 0.1145 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0074 | 0.1082 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0135 | 0.1028 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0023 | 0.0135 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0087 | 0.1314 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.008 | 0.1179 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.0985 | 0.8354 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.3636 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0023 | 0.0135 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0087 | 0.1314 | 1 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.008 | 0.1179 | 1 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.3636 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0023 | 0.0135 | 0.1028 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.008 | 0.1179 | 1 |
Treponema pallidum | polypeptide deformylase (def) | 0.0558 | 1 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.3636 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 1 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0558 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.3636 | 0.5 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0023 | 0.0135 | 0.1145 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0558 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.3636 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 1 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.008 | 0.1179 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 1 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0074 | 0.1082 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.0135 | 0.1145 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0023 | 0.0135 | 0.1145 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.26 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 1.4 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Stability (ADMET) | = 57.5 % | Metabolic stability of the compound in human blood assessed as compound remaining at 2000 ng/mL after 2 hrs | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.